Trial Profile
Comparative Antiresorptive Efficacy of Alendronate or Raloxifene Following Discontinuation of Denosumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Alendronic acid (Primary) ; Denosumab (Primary) ; Raloxifene (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 05 Jun 2022 Planned End Date changed from 1 Jan 2025 to 1 Aug 2023.
- 05 Jun 2022 Planned primary completion date changed from 1 Aug 2024 to 1 Feb 2023.
- 05 Jun 2022 Status changed from recruiting to active, no longer recruiting.